In HR+/HER- early breast cancer, the DFS benefits of adjuvant ribociclib plus NSAI treatment compared to NSAI alone persisted even a year after treatment completion.

Circulating tumour DNA-guided adjuvant atezolizumab prolongs disease-free and overall survival in patients with ...

Muscle-invasive bladder cancer management is challenging for cisplatin-ineligible patients due to limited treatment options and high recurrence rates. The Padcev-Keytruda combination therapy ...

Computational tool improves recombinant virus design efficiency and yield.This innovative in-house development is a key component of Transgene’s ...

ATHENS, Greece — Real-world data confirm that complete nodal dissection following a positive sentinel lymph node biopsy in patients with stage III melanoma and micrometastases does not significantly ...

Adjuvant trastuzumab deruxtecan (T-DXd; Enhertu) significantly improved invasive disease-free survival compared with ...

The management of advanced thyroid cancer requires careful consideration of histology, molecular profiling, and treatment ...

Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across ...

Adjuvant radiation and endocrine therapy significantly reduce locoregional recurrence in early-stage breast cancer post-lumpectomy, especially in low-risk patients. Radiation therapy notably decreases ...

Dr Vishal A. Patel discusses the breakthrough in treating high-risk cutaneous squamous cell carcinoma with FDA-approved ...

NOTE. Extended FU data were received for 490 patients. Eighty-three patients had already died at the time of the 2-year analysis. Nine patients in the PD-1–treated arm and seven patients in the TT arm ...

Persistent depression during adjuvant cancer therapy increases treatment toxicity and significantly reduces quality of life, ...